The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.
Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X, Liang Z. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Annals Of Translational Medicine 2019, 7: 429. PMID: 31700865, PMCID: PMC6803170, DOI: 10.21037/atm.2019.09.03.Peer-Reviewed Original ResearchHFD/streptozotocinHigh-fat dietDiabetes mellitusExperimental steatohepatitisHepatic damageNOD-like receptor family pyrin domainSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsDiabetic liver injuryEfficacy of dapagliflozinROS-NLRP3 inflammasomeSGLT2 inhibitor dapagliflozinHepatic reactive oxygen speciesCotransporter 2 inhibitorsReactive oxygen speciesFamily pyrin domainHepatic lipid accumulationSterile inflammatory responseMajor clinical consequencesDAPA treatmentDM patientsInhibitor dapagliflozinLiver injuryLiver diseaseLiver steatosis